Search results
Johnson & Johnson (JNJ) Up 5.3% Since Last Earnings Report: Can It Continue?
Zacks via Yahoo Finance· 1 year agoA month has gone by since the last earnings report for Johnson & Johnson (JNJ). Shares have added...
Blue Shield of California looks to cut reliance on CVS, taps Amazon
Reuters via Yahoo Finance· 8 months ago(Reuters) -Blue Shield of California plans to stop using most of CVS Health's pharmacy benefit...
Blue Shield of California is promising a simpler, cheaper pharmacy benefits model. Can it deliver?
Healthcare Dive via Yahoo Finance· 6 months agoBig questions hang over the California health insurer's bold experiment — having five vendors carry...
Johnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 months agoJohnson & Johnson (NYSE:JNJ) Q3 2023 Earnings Call Transcript October 17, 2023 Operator: Good...
Why Is Johnson & Johnson (JNJ) Down 1.8% Since Last Earnings Report?
Zacks via Yahoo Finance· 2 years agoA month has gone by since the last earnings report for Johnson & Johnson (JNJ). Shares have lost...
Biden touts next steps on 'Cancer Moonshot' in speech at JFK library
NBC News via Yahoo News· 2 years agoBiden will announce steps to expand on his "Cancer Moonshot" initiative to prevent deaths from the...
J&J (JNJ) Q1 Earnings & Sales Top, 2023 View Up, Stock Rises
Zacks via Yahoo Finance· 1 year agoJohnson & Johnson’s JNJ first-quarter 2023 earnings came in at $2.68 per share, which beat the Zacks...
J&J (JNJ) to Begin Q4 Earnings Season for Pharma Sector
Zacks via Yahoo Finance· 1 year agoGrowth in J&J's (JNJ) Pharma unit is expected to have been driven by drugs like Darzalex and...
Is the "New" Johnson & Johnson Stock a Buy With Its Improved Profit Outlook?
Motley Fool· 6 months agoJohnson & Johnson (NYSE: JNJ) is no longer the same company that investors have known for decades....
J&J (JNJ) Q4 Earnings Beat, Sales Miss, 2023 EPS View Upbeat
Zacks via Yahoo Finance· 1 year agoJ&J (JNJ) beats estimates for fourth-quarter earnings but misses the same for sales. Its EPS outlook...
